Find Funding for Translational Research in Maternal and Pediatric Therapeutics

Funding News Edition: April 05, 2023
See more articles in this edition

Consider applying for R01 or R21 grant funds to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities, through the following reissued notices of funding opportunities (NOFOs):

For help choosing between the standard independent R01 or the exploratory/developmental research R21 NOFO, check the activity code description in Section V of each NOFO and discuss your application plans with the scientific/research contacts listed below. You can also find general NIAID advice at Comparing Popular Research Project Grants—R01, R03, and R21.

Scientific Summary

Both opportunities support translational and clinical research to:

  1. Advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact.
  2. Enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation.
  3. Discover and develop novel therapeutics, enhance use of existing drugs, or repurpose drugs for safer and more effective medications in pregnant and lactating persons, neonates, and children.

Translational research in maternal and pediatric pharmacology and therapeutics encompasses tools, models, biomarkers, other technologies, and new and repurposed therapeutics that drive innovation for the safe and effective treatment of fetal, pediatric, obstetric, and lactating patients, including those with disabilities.

NIAID Statement of Interest

NIAID and several other NIH institutes and centers (ICs) co-sponsor these NOFOs. For applications to NIAID, be sure to read the “Scientific Interest of the National Institute of Allergy and Infectious Diseases (NIAID)” section of your chosen NOFO. Our statement of scientific interest begins with the following summary:

“NIAID is interested in advancing discovery and development of treatment and prevention of infectious, immune-mediated, and allergic diseases and precision medicine approaches for fetal, neonatal, pediatric, pregnant, and lactating persons….”

Your proposed science must fall within the mission areas described at NIAID Role in Research. Note that NIAID does not support Clinical Trials for these opportunities.

Application Details and Contact Information

For the R01 NOFO, the scope of your proposed research should determine the project period up to a maximum of 5 years. Your application budget is not limited, but be sure to propose a budget that reflects the actual needs of the project.

For the R21 NOFO, your project scope should determine the project period up to a maximum of 2 years. Your total direct costs for the project period may not exceed $275,000. You may request no more than $200,000 in direct costs in any single year.

Your first due dates are June 5, 2023, for an R01 or June 16, 2023, for an R21. After that, the NOFOs follow NIH Standard Due Dates for R01s and R21s until the opportunities expire on May 8, 2026. Be sure to submit your optional Letter of Intent at least 30 days before you apply.

If you plan to apply to NIAID, we encourage you to reach out to Dr. Tania Lombo Rodriguez, NIAID’s scientific/research contact for both NOFOs, at or 301-761-7612. For applications to other ICs or if you have inquiries related to peer review and grants management, find the relevant contacts in Section VII. Agency Contacts of each NOFO.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on